Rhythm Pharmaceuticals (RYTM) Operating Income (2020 - 2025)
Historic Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' Operating Income fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported Operating Income of -$52.7 million as of Q3 2025, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' 5-year Operating Income high stood at -$34.4 million for Q1 2021, and its period low was -$139.9 million during Q1 2024.
- Moreover, its 5-year median value for Operating Income was -$44.2 million (2021), whereas its average is -$49.7 million.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 16629.42% in 2024, then skyrocketed by 6639.86% in 2025.
- Rhythm Pharmaceuticals' Operating Income (Quarter) stood at -$51.0 million in 2021, then grew by 17.43% to -$42.1 million in 2022, then increased by 1.99% to -$41.3 million in 2023, then grew by 0.02% to -$41.3 million in 2024, then fell by 27.63% to -$52.7 million in 2025.
- Its Operating Income stands at -$52.7 million for Q3 2025, versus -$45.3 million for Q2 2025 and -$47.0 million for Q1 2025.